European Archives - Page 47 of 1131 - European Medical Journal

Early Health Technology Assessment to Detect Incidental Pulmonary Embolisms on CT

Incidental pulmonary embolisms (IPE) on CT are missed in up to 70% of cases. While AI tools for IPE detection exist, an evaluation on if…

Patients’ Perception of Radiographers’ Communication Skills During Planar X-Ray Imaging

To explore patients’ perception of radiographers’ communication skills during planar X-ray imaging examinations at a general hospital…

Novel Therapies Require Novel Imaging

With an impressive attendance of 20,522 participants from 131 countries, the European Congress of Radiology (ECR) 2025 was an epicentre…

Diagnostic Performance of Neural Network Algorithms in Skull Fracture Detection on CT Scans

Radiologists who evaluate CT scans have diagnostic challenges due to the complexity of underlying anatomy and the potential intricacy of…

EBMT 2025: Long-Term Outcomes of CAR-T Cell Therapy in Relapsed Lymphoma

A study at EBMT 2025 shows improved outcomes for relapsed lymphoma patients using CAR-T cell therapy with stem cell transplantation.

EBMT 2025: Stem Cell Treatment for Early-Onset IBD

HSCT shows promising results as a cure for very early-onset inflammatory bowel disease caused by IL-10 receptor deficiency.

Targeting Senescent Cells to Treat MASLD Effectively

Recent studies have identified a gene signature known as the senescent hepatocyte gene signature that tracks with MASLD progression.

EBMT 2025: Transplantation Outcomes in MDS/AML

Explore EBMT 2025 results on transplantation outcomes for Myelodysplastic Syndrome and Acute Myeloid Leukaemia, highlighting survival and relapse data.

EBMT 2025: Adoptive Cell Therapy for Infections in Immunocompromised

Adoptive cell therapy with memory T lymphocytes clears infections in patients that are immunocompromised, showing promising results at EBMT 2025.

EBMT 2025: Are Functional Respiratory Tests Key for Screening in CAR-T Cell Therapy?

Functional respiratory tests may help predict outcomes in anti-CD19 CAR-T cell therapy, as shown in EBMT 2025 research.